- Home
- GNLX vs KLRS Comparison
GNLX vs KLRS Comparison
Compare GNLX & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- KLRS
- Stock Information
- Founded
- GNLX 2001
- KLRS 2019
- Country
- GNLX United States
- KLRS United States
- Employees
- GNLX N/A
- KLRS N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- KLRS Health Care
- Exchange
- GNLX Nasdaq
- KLRS Nasdaq
- Market Cap
- GNLX 129.9M
- KLRS 129.0M
- IPO Year
- GNLX 2023
- KLRS N/A
- Fundamental
- Price
- GNLX $3.53
- KLRS $2.69
- Analyst Decision
- GNLX Strong Buy
- KLRS Buy
- Analyst Count
- GNLX 5
- KLRS 1
- Target Price
- GNLX $16.20
- KLRS N/A
- AVG Volume (30 Days)
- GNLX 153.8K
- KLRS 55.8K
- Earning Date
- GNLX 08-13-2025
- KLRS 08-15-2025
- Dividend Yield
- GNLX N/A
- KLRS N/A
- EPS Growth
- GNLX N/A
- KLRS N/A
- EPS
- GNLX N/A
- KLRS N/A
- Revenue
- GNLX N/A
- KLRS N/A
- Revenue This Year
- GNLX N/A
- KLRS N/A
- Revenue Next Year
- GNLX N/A
- KLRS N/A
- P/E Ratio
- GNLX N/A
- KLRS N/A
- Revenue Growth
- GNLX N/A
- KLRS N/A
- 52 Week Low
- GNLX $1.60
- KLRS $2.28
- 52 Week High
- GNLX $5.89
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- GNLX 58.36
- KLRS N/A
- Support Level
- GNLX $3.30
- KLRS N/A
- Resistance Level
- GNLX $3.60
- KLRS N/A
- Average True Range (ATR)
- GNLX 0.26
- KLRS 0.00
- MACD
- GNLX 0.00
- KLRS 0.00
- Stochastic Oscillator
- GNLX 75.71
- KLRS 0.00
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.